Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA)
CUSIP: 90240B106
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / COMMON STOCK, $0.0001 PAR VALUE PER SHARE
- Shares outstanding
- 53,571,429
- Total 13F shares
- 46,814,701
- Share change
- -54,749
- Total reported value
- $748,570,507
- Price per share
- $15.99
- Number of holders
- 76
- Value change
- -$1,810,347
- Number of buys
- 45
- Number of sells
- 31
Quarterly Holders Quick Answers
What is CUSIP 90240B106?
CUSIP 90240B106 identifies TYRA - Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 90240B106:
Top shareholders of TYRA - Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
19%
|
10,416,609
|
$170,832,388 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
3/4/5
|
Company · Other* |
12%
|
6,448,359
|
$105,753,088 | — | 31 Mar 2024 | |
| BVF INC/IL |
13F
|
Company |
8.7%
|
4,661,194
|
$76,443,582 | — | 31 Mar 2024 | |
| Canaan Partners XI LLC |
13F
|
Company |
8.2%
|
4,409,991
|
$72,323,852 | — | 31 Mar 2024 | |
| Nextech Invest Ltd. |
13F
|
Company |
7.6%
|
4,055,861
|
$66,516,120 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
7.4%
|
3,977,208
|
$65,226,211 | — | 31 Mar 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
3.7%
|
1,989,103
|
$32,621,289 | — | 31 Mar 2024 | |
| Alta Partners NextGen Fund II Management, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,080,296
|
$26,844,267 | — | 17 Sep 2021 | |
| Fairmount Funds Management LLC |
13F
|
Company |
2.6%
|
1,393,329
|
$22,850,596 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.9%
|
1,044,225
|
$17,125,289 | — | 31 Mar 2024 | |
| 5AM Venture Management, LLC |
13F
|
Company |
1.8%
|
939,298
|
$15,404,487 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.7%
|
899,800
|
$14,756,720 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.6%
|
832,220
|
$13,648,408 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.4%
|
768,638
|
$12,605,663 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.2%
|
669,159
|
$10,974,208 | — | 31 Mar 2024 | |
| Sio Capital Management, LLC |
13F
|
Company |
1%
|
535,741
|
$8,786,152 | — | 31 Mar 2024 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.96%
|
515,190
|
$8,449,116 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
1,069,932
|
$7,039,083 | — | 17 Sep 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.78%
|
416,808
|
$6,837,116 | — | 31 Mar 2024 | |
| First Turn Management, LLC |
13F
|
Company |
0.71%
|
381,210
|
$6,251,844 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.71%
|
380,597
|
$6,241,791 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.55%
|
292,234
|
$4,792,638 | — | 31 Mar 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.51%
|
272,150
|
$4,463,000 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.38%
|
203,709
|
$3,340,828 | — | 31 Mar 2024 | |
| Canaan XI L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
473,396
|
$3,114,472 | — | 17 Sep 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.29%
|
156,472
|
$2,566,141 | — | 31 Mar 2024 | |
| Nicholas Investment Partners, LP |
13F
|
Company |
0.29%
|
152,968
|
$2,508,675 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.28%
|
152,212
|
$2,496,277 | — | 31 Mar 2024 | |
| Robert L. Hudkins |
3/4/5
|
Chief Technology Officer |
—
class O/S missing
|
273,576
|
$1,799,857 | — | 15 Sep 2022 | |
| Ronald Swanson V |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
378,254
mixed-class rows
|
$1,797,738 | — | 06 Sep 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.19%
|
101,788
|
$1,669,324 | — | 31 Mar 2024 | |
| Esther van den Boom |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
240,542
|
$1,582,525 | — | 15 Sep 2022 | |
| Auour Investments LLC |
13F
|
Company |
0.16%
|
85,020
|
$1,394,328 | — | 31 Mar 2024 | |
| OPPENHEIMER & CO INC |
13F
|
Company |
0.11%
|
59,576
|
$977,046 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.1%
|
54,400
|
$892,000 | — | 31 Mar 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.09%
|
48,090
|
$788,676 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
43,735
|
$717,254 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.08%
|
41,742
|
$684,569 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.07%
|
35,237
|
$577,887 | — | 31 Mar 2024 | |
| Hiroomi Tada |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
86,435
|
$568,656 | — | 15 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
33,032
|
$541,725 | — | 31 Mar 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.06%
|
32,149
|
$527,244 | — | 31 Mar 2024 | |
| Piyush R. Patel |
3/4/5
|
Chief Development Officer |
—
class O/S missing
|
73,794
|
$485,491 | — | 21 Feb 2023 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.05%
|
28,300
|
$464,120 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.05%
|
25,713
|
$421,693 | — | 31 Mar 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.05%
|
24,937
|
$408,967 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
20,998
|
$344,362 | — | 31 Mar 2024 | |
| Legato Capital Management LLC |
13F
|
Company |
0.04%
|
20,259
|
$332,248 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.04%
|
19,643
|
$322,145 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.03%
|
16,887
|
$276,947 | — | 31 Mar 2024 |
Institutional Holders of Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) as of Q2 2024
As of 30 Jun 2024,
Tyra Biosciences, Inc. - COMMON STOCK, $0.0001 PAR VALUE PER SHARE (TYRA) was held by
76 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,814,701 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Boxer Capital, LLC, BVF INC/IL, Canaan Partners XI LLC, Nextech Invest Ltd., FMR LLC, TCG Crossover Management, LLC, BlackRock Inc., VANGUARD GROUP INC, and PERCEPTIVE ADVISORS LLC.
This page lists
76
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
75
Q2 2024 holders
76
Holder diff
1
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.